Previous 10 | Next 10 |
Diffusion Pharmaceuticals press release (NASDAQ:DFFN): FY GAAP EPS of -$0.25. As of December 31, 2021, the Company reported a total of $37.3M in cash and cash equivalents. For further details see: Diffusion Pharmaceuticals GAAP EPS of -$0.25
Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO Trial Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start $37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operations Through 2023 CH...
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas ...
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to a...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to a...
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to a...
3 Biotech Penny Stocks to Watch With the New Variant in Mind With another interesting day of trading penny stocks and blue chips off to a good start, it’s clear that volatility is here to stay. Although it may have seemed like things were calming down in the past few weeks, the e...
Diffusion Pharmaceuticals (NASDAQ:DFFN) has dosed the first participants in its Altitude Trial, which will evaluate the Company’s lead product candidate, trans sodium crocetinate (TSC), in normal healthy volunteers. Shares up 3.6% premarket at $0.40. The Altitude Trial is a d...
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to a...
Diffusion Pharmaceuticals (NASDAQ:DFFN): Q3 GAAP EPS of -$0.12 misses by $0.08. Cash and cash equivalents of $40.33M Press Release For further details see: Diffusion Pharmaceuticals EPS misses by $0.08
News, Short Squeeze, Breakout and More Instantly...
Diffusion Pharmaceuticals Inc. Company Name:
DFFN Stock Symbol:
NASDAQ Market:
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is one of today's top gainers. The company's shares are currently up 15.2% on the day to $4.6. Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product...
Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced...
NEW YORK, NY / ACCESSWIRE / April 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Univar Solutions Inc. (NYSE:UNVR)'s ...